

Appendix: Tables

1.	Sales January to September 2023 and 2022	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2023 vs. YTD September 2022	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to September 2023 and 2022

CHF millions	Nine months ended 30 September		% change	
	2023	2022	At CER	In CHF
Pharmaceuticals Division	33,622	33,189	9	1
United States	17,680	17,199	8	3
Europe	6,259	6,100	7	3
Japan	2,937	3,029	10	-3
International*	6,746	6,861	12	-2
Diagnostics Division	10,431	13,848	-18	-25
Roche Group	44,053	47,037	1	-6

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022

CHF millions	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022
Pharmaceuticals Div.	10,842	-6	12,362	9	11,699	9	10,982	7	10,941	11
United States	5,836	-6	6,123	1	5,853	6	5,890	7	5,937	11
Europe	1,996	4	2,043	-3	2,071	5	2,034	5	2,154	9
Japan	827	-27	1,920	69	1,390	18	820	8	727	1
International*	2,183	-3	2,276	4	2,385	13	2,238	6	2,123	17
Diagnostics Division	3,900	-4	3,882	-9	3,623	-28	3,475	-17	3,333	-5
Roche Group	14,742	-6	16,244	4	15,322	-3	14,457	0	14,274	7

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2023 vs. YTD September 2022

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	4,767	14	3,492	12	877	12	-	-	398	35
Hemlibra	3,112	19	1,862	17	637	22	281	15	332	36
Perjeta	2,995	6	1,101	2	615	-4	161	4	1,118	15
Tecentriq	2,791	11	1,476	7	628	14	313	9	374	24
Actemra/RoActemra	1,943	2	877	1	583	1	232	3	251	6
Vabysmo	1,613	**	1,320	449	185	**	70	236	38	**
Xolair	1,601	4	1,601	4	-	-	-	-	-	-
Kadcyla	1,486	2	568	-3	446	-9	77	-14	395	29
Herceptin	1,261	-17	258	-28	271	-15	24	-33	708	-13
MabThera/Rituxan	1,260	-15	761	-20	140	-7	19	-13	340	-8
Avastin	1,210	-20	370	-22	78	-48	250	-25	512	-8
Alecensa	1,126	9	340	8	220	5	157	6	409	12
Evryssi	1,065	45	381	15	374	54	67	29	243	115
Activase/TNKase	903	8	859	8	-	-	-	-	44	7
Phesgo	817	66	320	56	384	53	-	-	113	186
Gazyva	615	22	297	25	174	25	28	-17	116	24
Polivy	605	126	230	100	136	70	167	181	72	372
Ronapreve	532	-5	-	-	-	-100	531	33	1	-99
Lucentis	396	-48	396	-48	-	-	-	-	-	-
Pulmozyme	342	-12	229	-14	57	-18	-	14	56	6
Enspryng	186	55	52	47	12	108	110	46	12	249
Rozlytrek	63	27	33	3	12	40	6	27	12	180

Luxturna	43	121	43	121	-	-	-	-	-	-
Lunsumio	43	**	37	-	6	**	-	-	-	-
Cotellic	39	23	18	81	8	-22	-	-	13	15
Gavreto	32	66	18	21	5	10	-	-	9	**
Xofluza	32	**	3	65	-	-	-	-	29	**
Columvi	10	-	7	-	2	-	-	-	1	-
Susvimo	3	-23	3	-23	-	-	-	-	-	-
Pharma other	2,731	-14	728	-27	409	-28	444	-8	1,150	1
Pharma total sales	33,622	9	17,680	8	6,259	7	2,937	10	6,746	12

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022
Ocrevus	1,517	16	1,609	18	1,636	14	1,564	15	1,567	12
Hemlibra	952	23	1,045	24	1,034	24	1,053	17	1,025	17
Perjeta	1,029	5	997	4	1,049	11	1,033	6	913	0
Tecentriq	934	9	1,025	24	920	15	933	8	938	10
Actemra/RoActemra	584	-42	662	-22	676	-12	620	2	647	21
Vabysmo	173	-	309	-	432	*	525	*	656	309
Xolair	600	8	583	6	479	5	552	4	570	3
Kadcyla	516	6	490	-3	509	5	492	-5	485	5
Herceptin	493	-23	470	-22	477	-17	401	-22	383	-13
MabThera/Rituxan	479	-19	479	-20	459	-17	423	-17	378	-13
Avastin	510	-28	470	-25	416	-24	421	-17	373	-18
Alecensa	382	11	386	10	372	9	386	11	368	7
Evrysdi	293	93	326	59	363	62	342	36	360	41
Activase/TNKase	322	-5	296	-27	302	23	319	9	282	-4
Phesgo	201	76	214	73	241	72	276	67	300	61
Gazyva	190	9	191	9	197	24	205	20	213	22
Polivy	113	63	147	97	150	96	203	129	252	144
Ronapreve	22	-92	1,048	118	567	9	-17**	-98	-18**	-100
Lucentis	228	-39	212	-40	167	-35	132	-55	97	-53
Pulmozyme	135	-3	129	-15	127	-5	111	-15	104	-15

* Over 500%

**Effect of currency revaluation (CHF/JPY) on CHF567m Q1 2023 Ronapreve sales

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022
Ocrevus	1,143	17	1,204	15	1,188	13	1,158	14	1,146	10
Hemlibra	586	16	632	21	631	21	616	14	615	15
Perjeta	395	0	398	13	392	8	371	6	338	-6
Tecentriq	500	3	524	20	507	14	493	5	476	4
Actemra/RoActemra	250	-61	282	-42	296	-22	278	6	303	33
Vabysmo	152	-	264	-	360	*	428	458	532	276
Xolair	600	8	583	6	479	5	552	4	570	3
Kadcyla	204	-8	201	-4	198	-3	188	-5	182	-2
Herceptin	113	-29	100	-29	91	-37	85	-23	82	-21
MabThera/Rituxan	311	-14	314	-15	274	-21	260	-19	227	-19
Avastin	155	-31	137	-26	133	-25	123	-20	114	-19
Alecensa	124	22	122	13	106	7	115	14	119	4
Evrysdi	121	13	122	20	124	13	131	19	126	14
Activase/TNKase	305	-6	278	-29	288	23	304	9	267	-5
Phesgo	79	62	87	58	98	62	111	53	111	54
Gazyva	90	7	94	11	99	32	95	18	103	24
Polivy	44	57	44	65	46	35	78	91	106	161
Ronapreve	-	-	-	-	-	-	-	-	-	-
Lucentis	228	-39	212	-40	167	-35	132	-55	97	-53
Pulmozyme	96	2	89	-17	83	-5	75	-16	71	-19

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022
Ocrevus	269	11	267	26	298	11	286	16	293	10
Hemlibra	182	36	199	27	206	27	213	18	218	22
Perjeta	204	-15	210	-15	220	1	193	-12	202	0
Tecentriq	190	17	221	23	195	11	203	7	230	22
Actemra/RoActemra	182	-3	200	-14	193	-8	190	0	200	11
Vabysmo	4	-	18	-	44	-	59	*	82	*
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	158	3	163	-2	154	-6	144	-15	148	-6
Herceptin	96	-18	93	-27	97	-17	86	-18	88	-9
MabThera/Rituxan	51	-18	48	-21	51	0	45	-9	44	-11
Avastin	42	-47	35	-56	30	-45	27	-51	21	-50
Alecensa	69	5	74	3	73	3	75	5	72	5
Evryssi	101	216	100	116	113	74	128	61	133	35
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Phesgo	100	107	104	61	114	59	126	55	144	47
Gazyva	49	-9	48	-8	55	25	56	22	63	29
Polivy	38	88	48	144	40	93	40	76	56	53
Ronapreve	37	-54	-1	-100	-	-100	-	-100	-	-100
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	22	-12	23	-13	20	-16	19	-20	18	-18

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	97	22	100	14	92	24	100	19	89	5
Perjeta	55	-1	59	3	53	2	56	5	52	6
Tecentriq	108	0	117	6	105	12	109	11	99	5
Actemra/RoActemra	82	-4	86	6	77	0	80	5	75	4
Vabysmo	17	-	23	-	21	-	25	299	24	77
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	33	16	30	2	26	-8	26	-17	25	-15
Herceptin	12	-28	11	-28	9	-30	8	-34	7	-35
MabThera/Rituxan	7	-13	8	-23	6	-13	7	-15	6	-11
Avastin	115	-19	112	-21	91	-21	86	-25	73	-28
Alecensa	55	4	59	7	50	5	57	7	50	5
Evrysdi	22	*	24	83	21	47	24	25	22	21
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Phesgo	-	-	-	-	-	-	-	-	-	-
Gazyva	11	-17	11	-12	8	-35	12	1	8	-18
Polivy	25	34	45	92	51	169	57	194	59	178
Ronapreve	-15**	-100	1,028	313	567	33	-18***	-	-18***	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	-1	1	38	-	18	-	-4	-	34

* Over 500%

Effect of currency revaluation (CHF/JPY) on CHF483m Q1 2022 (**) and on CHF567m Q1 2023 (***) Ronapreve sales

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022	Q3 2023	% change vs. Q3 2022
Ocrevus	105	26	138	29	150	32	120	23	128	50
Hemlibra	87	53	114	45	105	38	124	31	103	39
Perjeta	375	30	330	13	384	22	413	18	321	4
Tecentriq	136	30	163	70	113	34	128	23	133	18
Actemra/RoActemra	70	-44	94	51	110	10	72	-9	69	20
Vabysmo	-	-	4	-	7	-	13	**	18	**
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	121	46	96	-3	131	42	134	11	130	41
Herceptin	272	-22	266	-17	280	-7	222	-22	206	-11
MabThera/Rituxan	110	-32	109	-28	128	-12	111	-14	101	4
Avastin	198	-23	186	-16	162	-19	185	1	165	-5
Alecensa	134	9	131	13	143	14	139	13	127	10
Evrysdi	49	231	80	73	105	189	59	39	79	134
Activase/TNKase	17	12	18	20	14	17	15	8	15	-1
Phesgo	22	20	23	**	29	232	39	206	45	151
Gazyva	40	91	38	62	35	27	42	29	39	18
Polivy	6	135	10	86	13	340	28	339	31	422
Ronapreve	-	-99	21	-81	-	-100	1	-97	-	-100
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	17	-16	16	-9	24	10	17	-5	15	14

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%